US Stock MarketDetailed Quotes

ADAG Adagene

Watchlist
  • 1.780
  • -0.040-2.20%
Close Mar 20 16:00 ET
78.80MMarket Cap-2.45P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Feb 27 21:03
    NEWS
    $Adagene (ADAG.US)$
    Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer
    2 minutes ago, 5:00 AM PST
    Via GlobeNewswire
    ADAG
    Share
    - Trial to begin enrolling in April; expected primary completion in mid-2027 -
    - Primary study endpoint of rate of major pathological response -
    SAN DIEGO and SUZHOU, China, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of no...
    Jaguar8
    Jaguar8
    Jan 27 20:02
    NEWS
    $Adagene (ADAG.US)$
    Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
    Monday, 27th January at 7:00 am
    Muzastotug (ADG126), an Anti-CTLA-4 SAFEbody® in Combination with pembrolizumab showed 33% overall response rate in microsatellite stable colorectal cancer
    Four confirmed partial responses out of twelve patients with 20 mg/kg loading dose followed by 10 mg/kg Q3W + ...
    Trytosaveabit
    Trytosaveabit
    Jan 22 06:33
    Watching for data outadis! Could, COULD serve as a catalyst for a move?? NFA
    $Adagene (ADAG.US)$ Adagene To Share Updated Clinical Data From ADG126 In Microsatellite Stable Colorectal Cancer At ASCO Gastrointestinal Cancers Symposium On January 25, 2025.
    New data will include initial results from the 20 mg/kg loading dose followed by 10 mg/kg Q3W in combination with pembrolizumab.
    Jaguar8
    Jaguar8
    Jan 22 06:00
    NEWS
    $Adagene (ADAG.US)$
    Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
    Tuesday, 21st January at 5:00 pm
    SAN DIEGO and SUZHOU, China, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced it will share updated clinical data from ADG126 in micro...
    Jaguar8
    Jaguar8
    Jan 14 21:08
    NEWS
    $Adagene (ADAG.US)$
    Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025
    Tuesday, 14th January at 8:00 am
    SAN DIEGO and SUZHOU, China, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced it will host a virtual key opinion leader (KOL) event on Saturday,...
Read more
Market Insights
Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

Symbol Mini Chart % Chg
DexCom
DXCM
+2.36%
YETI Holdings
YETI
+1.26%
New Fortress Energy
NFE
+0.88%
Dorian LPG
LPG
+0.52%
Collegium Pharmaceutical
COLL
+0.27%

Unlock the Full List